Melanoma Institute Australia
20
7
11
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.0%
2 terminated/withdrawn out of 20 trials
71.4%
-15.1% vs industry average
10%
2 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
Role: lead
The Multicentre Selective Lymphadenectomy Trial - 3
Role: lead
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
Role: lead
Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma
Role: lead
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Role: lead
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Role: lead
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Role: lead
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Role: lead
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
Role: lead
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Role: lead
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
Role: lead
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
Role: lead
Personalised Immunotherapy Platform
Role: lead
Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
Role: collaborator
Radiotherapy & Combi in Metastatic Melanoma
Role: collaborator
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
Role: lead
Radiotherapy or Imiquimod in Complex Lentigo Maligna
Role: collaborator
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Role: lead
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Role: lead
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
Role: collaborator
All 20 trials loaded